Oral Antibiotics Market Size, Share Global Analysis Report, 2023 – 2030

Industry Insights

[223+ Pages Report] According to Facts and Factors, the global oral antibiotics market size was valued at USD 22.58 billion in 2022 and is predicted to surpass USD 30.10 billion by the end of 2030. The oral antibiotics industry is expected to grow by a CAGR of 3.66%.

Market Overview

Oral antibiotics are medications ingested through the mouth and are absorbed in the gastrointestinal tract to treat different bacterial infections. These are a widely used form of antibiotic therapy. The oral antibiotic comes in different formulations, including chewable tablets, liquids, capsules, and others. It is prescribed by the healthcare professionals to combat the bacterial infections in different parts of the body.

Key Insights

• As per the analysis shared by our research analyst, the global oral antibiotics market size is estimated to grow annually at a CAGR of around 3.66% over the forecast period (2023-2030).
• In terms of revenue, the global oral antibiotics market size was valued at around USD 22.58 billion in 2022 and is projected to reach USD 30.10 billion by 2030.
• High prevalence of bacterial infections is driving the growth of the global oral antibiotics market.
• Based on the drug type, the branded segment is growing at a high rate and is projected to dominate the global market.
• Based on the application, the community-acquired respiratory tract infections segment is projected to swipe the largest market share.
• Based on the spectrum of activity, the broad-spectrum antibiotics segment is expected to dominate the global market.
• Based on the class, the beta inhibitor & beta-lactamase inhibitors segment is expected to dominate the global market.  
• Based on region, North America is expected to dominate the global market during the forecast period.

Growth Drivers

• High prevalence of bacterial infections is likely to drive the growth of the global market.

The growing prevalence of bacterial infections like respiratory tract infections, skin infections, and urinary tract infections is driving the demand for oral antibiotics. However, the growing burden of infectious diseases is likely to contribute heavily to the growth of the global oral antibiotics market.

Also, the surge in antibiotic-resistant bacteria is another global health concern. There is a significant increase in bacterial resistance, which drives the requirement for new and more potent antibiotics. The increase in demand drives the research and development activities in the pharmaceutical sector, thereby contributing towards the growth of the industry.

For instance, Sandoz successfully took over GSK's cephalosporin antibiotics business in October 202. The company acquired the rights to three established brands: Fortum, Zinacef, and Zinnat.

Restraints

• Strict regulatory approval processes are likely to hamper the growth of the global market.

Regulatory agents like the FDA and EMA have a strict approval process for new antibiotics. Therefore, the lengthy and complex regulatory pathways are expected to slow down the growth trajectory of the global oral antibiotics market.

Opportunities

• Innovation in antibiotic development is expected to foster growth opportunities in the global market.

Advancements in research and development, like the discovery of new antibiotic compounds along with the developments in existing formulations, are further expected to widen the scope of the oral antibiotics industry. Innovation of new drug delivery systems and combination therapies further improve the efficacy and convenience of oral antibiotics.

Also, the rising awareness among patients regarding the importance of completing the prescribed antibiotic courses contributes to the market’s growth. They are seeking appropriate medical care for the bacterial infections to avoid future inconveniences. Patient education campaigns and public health initiatives are playing an active role in boosting the growth opportunities in the industry.

For instance, Teva Pharmaceuticals Industries Ltd. is said to come up with 500mg and 250mg strength generic erythromycin tablets in May 2021. It is used to treat a variety of bacterial infections.

Challenges

• Generic competition and pricing pressure are huge challenges in the global market.

The availability of generic alternatives, particularly after the expiration of patents for branded antibiotics, is increasing the competition among brands. Furthermore, pricing pressure is a major issue for the brand because generic drugs are often more affordable, thereby impacting the revenue potential for all the branded oral antibiotics. Therefore, such a landscape is expected to be a big challenge in the oral antibiotics industry.

Segmentation Analysis

The global oral antibiotics market can be segmented into drug type, application, spectrum of activity, class, and region.

On the basis of drug type, the market can be segmented into generic and branded. The branded segment accounts for the largest share of the oral antibiotics industry. Branded antibiotics are associated with a history of established efficacy, development, and research.

Branded drugs offer pharmaceutical companies an exclusive right to sell the drug for a specific period, which limits the competition and thereby contributes to the dominance of the segment. Moreover, pharmaceutical companies employ marketing strategies like promotional activities and direct-to-consumer advertising to position their branded antibiotics in the market.

On the basis of applications, the market can be segmented into dental, urinary tract infections, and community-acquired respiratory tract infections. The community-acquired respiratory tract infections segment is anticipated to dominate the global oral antibiotics market during the forecast period. Community-acquired respiratory tract infections include infections of the lower respiratory tract and upper respiratory tract, which are outside of the healthcare settings. These infections are caused by various bacteria.

Also, various factors like antibiotic resistance, microbial patterns, and overall prevalence of respiratory infections influence the domination of the segment. Moreover, the effectiveness of oral antibiotics against the common respiratory pathogen and preference for outpatient treatment of respiratory infection is further expected to support the growth trajectory of the segment during the forecast period.

On the basis of the spectrum of activity, the market can be segmented into narrow-spectrum antibiotics and broad-spectrum antibiotics. The broad-spectrum antibiotics are expected to be a leading segment in the oral antibiotics industry. Broad-spectrum antibiotics are effective against a wide range of bacteria, both gram-negative and positive. These are often prescribed when the specific bacteria causing an infection are unknown or involve multiple numbers of bacteria.

However, the broad-spectrum antibiotic segment is highly preferred by patients and healthcare professionals because of their personality in treating a large spectrum of bacterial infections. Also, it is particularly important in cases where the agent isn’t yet recognized or needs rapid treatment. However, these are much in demand because of the high prevalence of polymicrobial infections, the need for high-impact treatment, and challenges in rapid diagnosis.

On the basis of class, the market can be segmented into macrolide and beta inhibitor & beta-lactamase inhibitors. The beta inhibitor & beta-lactamase inhibitors segment is expected to grow with a high CAGR during the anticipated period. The growth of the segment is highly driven by the growing prevalence of bacteria that produce beta-lacto enzymes. This issue of antibiotic resistance continues to be a global concern, and therefore, there is a high requirement for an effective solution. As a result, beta inhibitors emerged as an important medium to address this challenge, which is further likely to boost the growth of the segment.

Report Scope

Regional Analysis

• North America to dominate the global market.

North America accounts for the largest share of the global oral antibiotics market because of the fast-growing pharmaceutical industry in the region. The region encompasses the development, production, and distribution of antibiotics that are largely administered orally for the treatment of bacterial infections.

Moreover, Canada and the United States have well-established healthcare and pharmaceutical sectors, and thereby, the region is the major consumer of healthcare products. The regional market is also expected to be highly driven by the increasing prevalence of bacterial infections. Also, antibiotic resistance is surging globally, particularly in North America.

Therefore, there is a high need for resistant bacterial stains that necessitates ongoing research and development efforts to come up with new and improved antibiotics. Furthermore, the regulatory environment in North America plays an important role in drug approval and market taxes. Strict regulatory standards ensure the efficacy and safety of oral antibiotics, thereby offering a positive environment for the growth of the market.

Asia Pacific is expected to witness huge growth in the coming years because the region is home to a populous market with diverse healthcare requirements. The market in the region is influenced by various factors like economic growth, increasing healthcare awareness, and the growing burden of infectious diseases.

The high prevalence of infectious diseases like gastrointestinal infections, respiratory tract infections, and other bacterial infections is driving the need for oral antibiotics. Also, the diverse healthcare landscape in the region contributes to the variations in disease patterns, which poses a huge requirement for advanced oral antibiotics.

Competitive Analysis

The key players in the global oral antibiotics market include:

• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Limited
• Pfizer Inc.
• Novartis AG
• Lupin Limited
• Bayer AG
• Cipla Ltd
• Alkem Laboratories Ltd.
• Abbott Laboratories
• Teva Pharmaceutical Industries Limited

For instance, F Hoffmann Roche Ltd came up with a research collaboration and license agreement with Venatorx Pharmaceuticals in November 2021 to develop, characterize, and discover new molecule inhibitors of Penicillin Binding Proteins (PBPs) in gram-negative bacteria focusing on agents against carbapenem-resistant Enterobacterialis.

The global oral antibiotics market is segmented as follows:

By Drug Type Segment Analysis

• Generic
• Branded

By Application Segment Analysis

• Dental
• Urinary Tract Infections
• Community-Acquired Respiratory Tract Infections

By Spectrum Of Activity Segment Analysis

• Narrow-Spectrum Antibiotics
• Broad-Spectrum Antibiotics

By Class Segment Analysis

• Macrolide
• Beta Inhibitor & Beta-Lactamase Inhibitors

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America